Open Access
ISSN: 2321-8681
Volume-9, Issue-1 (January-June)
2022
Teprotumumab, New Era for Thyroid Eye Disease
Correspondence: rohit.kale242@gmail.com
Abstract
Thyroid eye disease is a progression of an autoimmune disease called Graves disease, which majorly affects eye orbits and its muscular tissues. It affects the patients by acting a impact on their quality of life by acting on patients visual balance along with facial disfiguring. In this review paper I will review as the development of monoclonal antibody called teprotumumab for treatment of thyroid eye disease along with its brief mechanism of action.
Cite this Article
Select a citation style to copy or import directly into your reference manager:
Kale Rohit, Shrikant Solnake, Dr. Deshmukh Tejeswini (2022). Teprotumumab, New Era for Thyroid Eye Disease. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June). https://doi.org/10.5281/zenodo.6620722
Kale Rohit, Shrikant Solnake, Dr. Deshmukh Tejeswini, 2022. Teprotumumab, New Era for Thyroid Eye Disease. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June).
Kale Rohit, Shrikant Solnake, Dr. Deshmukh Tejeswini. "Teprotumumab, New Era for Thyroid Eye Disease." Research and Reviews in Biotechnology and Biosciences Volume-9, Issue-1 (January-June) (2022).
@article{rrbb_202_KaleRohit,
title = {{Teprotumumab, New Era for Thyroid Eye Disease}},
author = {Kale Rohit, Shrikant Solnake, Dr. Deshmukh Tejeswini},
journal = {Research and Reviews in Biotechnology and Biosciences},
issn = {2321-8681},
year = {2022},
volume = {Volume-9, Issue-1 (January-June)},
doi = {https://doi.org/10.5281/zenodo.6620722}
}
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.